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A phase IV randomised, open-label pilot
study to evaluate switching from protease-
inhibitor based regimen to Bictegravir/
Emtricitabine/Tenofovir Alafenamide single
tablet regimen in Integrase inhibitor-naïve,
virologically suppressed HIV-1 infected
adults harbouring drug resistance
mutations (PIBIK study): study protocol for
a randomised trial
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Abstract
Background: Currently recommended boosted protease-inhibitor (bPI) regimens may be associated with increased
risk of cardiovascular or chronic kidney diseases; in addition, boosted regimens are particularly associated with
drug-drug interactions. Since both cardiovascular and renal disease, and polypharmacy, are common in ageing
people with HIV, there is a need for alternative efficacious regimens. bPI-based regimens are often the treatment of
choice for individuals with pre-treatment or treatment-acquired resistance but it is plausible that carefully selected
HIV-positive individuals with drug resistance, who are virologically suppressed on their current bPI regimen, could
maintain virological efficacy when switched to bictegravir, emtricitabine and tenofovir alafenamide (B/F/TAF) fixed
dose combination (FDC).
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Methods/design: A phase IV, investigator-initiated, multicentre, open label pilot, randomised two-arm study to
assess the safety and efficacy of switching from bPI regimen to B/F/TAF single tablet regimen in integrase inhibitor-
naïve, virologically suppressed adults with HIV-1 infection harbouring drug resistance mutations. Eligible individuals
will either continue on their bPI regimen or switch to B/F/TAF FDC. After 24 weeks, all participants in the bPI arm
will be switched to B/F/TAF and followed for a further 24 weeks and all participants will be followed for 48 weeks.
The primary efficacy endpoint is the proportion of participants with HIV-1 RNA < 50 copies/mL at week 24 using
pure virologic response whilst the secondary efficacy endpoint is the proportion of participants with HIV-1 RNA <
50 copies/mL at Week 48. Other secondary outcome measures include between arm comparisons of drug
resistance at virological failure, safety and tolerability and patient-reported outcome measures.
Discussion: We aim to provide preliminary evidence of the efficacy of switching to B/F/TAF in patients with
virological suppression on a bPI-based regimen who harbour select drug resistance mutations.
Trial registration: ISRCTN 44453201, registered 19 June 2019 and EudraCT 2018–004732-30.
Keywords: HIV, Antiretroviral drugs, Drug resistance, Protease inhibitor, B/F/TAF, Integrase inhibitor, Pilot, Phase IV
randomised trial
Background
Boosted darunavir and atazanavir are recommended as pre-
ferred boosted protease inhibitors (bPI) in the British HIV
Association treatment guidelines. However, boosted daru-
navir was associated with increased cardiovascular risk in a
large prospective observational study [1]. Although boosted
atazanavir has not been associated with increased cardio-
vascular risk [2], cohort studies indicate an increased risk of
chronic kidney disease [3]. In clinical trials, atazanavir re-
cipients experienced higher discontinuation rates from ad-
verse events than darunavir [2, 4] which were driven by
hyperbilirubinaemia and renal events. Ageing of people liv-
ing with HIV is resulting in increasing prevalence of cardio-
vascular and renal diseases; in addition, polypharmacy is
common due to comorbidities, pointing to an additional
limitation for bPI due to their particularly high potential for
drug-drug interactions [5, 6].
There is evidence from clinical trials that switching
from virologically suppressive bPI-based antiretroviral
therapy (ART) to regimens based on the newer strand
transfer integrase inhibitors, bictegravir [7] and dolute-
gravir [8] is safe and efficacious. These studies however
excluded individuals known to harbour HIV-1 drug re-
sistance. It is well established that HIV-positive individ-
uals that have either pre-treatment drug resistance
(PDR) or limited drug resistance following failure of
first-line ART achieve virological suppression on regi-
mens comprising a bPI plus two nucleos(t)ide reverse
transcriptase inhibitor (NRTIs) [9, 10]. In contrast, in
the SWITCHMRK study, switching virologically sup-
pressed individuals from a bPI to the integrase inhibitor
raltegravir resulted in an increased risk of virological
failure relative to individuals maintained on the bPI. A
post-hoc analysis suggested that this effect might be me-
diated by prior virological failure compromising the ac-
tivity of the NRTI backbone [11].
However, evidence indicates that second-generation
INSTIs, including bictegravir and dolutegravir, have an im-
proved barrier to resistance relative to first-generation com-
pounds and may overcome both PDR and limited
treatment-associated drug resistance. In the DAWNING
study, a second line switch to a regimen comprising the
INSTI dolutegravir plus 2 NRTIs, where at least one NRTI
was predicted to be fully active based on resistance analysis
at the time screening, was superior to a bPI plus 2 NRTIs
at 24 weeks in patients failing first line ART [12]. DAWN
ING study suggests second-generation INSTI like dolute-
gravir and by extension bictegravir are likely to be success-
ful in switch strategies in the presence of either PDR or
treatment-acquired drug resistance, including M184V/I or
thymidine analogue mutations (TAMs). A small, open label,
single arm study switched 37 patients (54% on a bPI-based
regimen) harbouring the lamivudine (3TC) and emtricita-
bine (FTC) associated mutation M184V/I to the fixed dose
combination (FDC) of elvitegravir/cobiscitat/emtricitabine/
tenofovir alafenamide with no virological failures observed
after 12 weeks of follow up [13]. Another study investigated
whether efficacy was maintained following a switch to bic-
tegravir/emtricitabine/tenofovir alafenamide FDC (B/F/
TAF) in individuals suppressed on either a PI-based regi-
men or the FDC of dolutegravir/abacavir/lamivudine
(DTG/ABC/3TC). Amongst the 572 participants on B/F/
TAF, 532 (93%) achieved virologic suppression (VL < 50
copies/mL), with missing virologic data accounting for
the majority of the remaining. Of the 572 partici-
pants, 405 (71%) had baseline resistance data available
determined by both historical genotypes and baseline
proviral DNA sequence; 52 (13%) of whom had NRTI
associated resistance mutation present. 35/36 (97%) of
those patients with archived F/TAF resistance muta-
tions maintained HIV-1 RNA suppression through
week 48 [14].
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It should be noted that in virologically suppressed pa-
tients it is often possible to recover proviral sequences
from cellular reservoirs in peripheral blood [14]. The
presence of archived drug resistance mutations identified
by sequencing proviral DNA is not necessarily reflective
of the full range of resistant variants that may have
emerged in an individual. Furthermore, it does not ne-
cessarily correlate with an increased risk of failure as in-
tegrated provirus is often defective [15] and reactivation
of a particular virus is likely to be a stochastic event. In
studies that examine drug activity in the presence of ar-
chived drug resistance, duration of follow up is crucial
because the likelihood that a particular latent virus car-
rying a certain mutation would reactivate may increase
with time, and the levels of adherence to ART over time
play a key modulating role. In the single arm switch
study referred to earlier, drug resistance sequencing
based on proviral DNA missed half of M184V/I muta-
tion present in historical genotype [13].
Taken together these studies suggest that B/F/TAF
may be effective in maintaining virological suppression
in patients with historical evidence of drug resistance
mutations. In light of this, we hypothesize that switching
HIV-positive patients who harbour selected drug resist-
ance mutations and are virologically suppressed on bPI




The PIBIK trial is a phase IV, investigator-initiated, pro-
spective, multicentre, open label pilot, randomised two
arm study to assess the safety and efficacy of switching
from a bPI-based regimen to B/F/TAF single tablet regi-
men in INSTI-naïve, virologically suppressed HIV-1 In-
fected adults harbouring drug resistance mutations. The
allocation ratio is 1:1 (Fig. 1).
Trial setting
Subjects will be enrolled from seven sexual health clinics
in England. These are:
 Brighton and Sussex University Hospitals NHS
Trust (BSUH), Brighton, UK. Other NHS Trust
within the Sussex HIV network will be able to refer
potentially eligible participants to BSUH for
screening and if enrolled will be followed up at
BSUH
 Barts Health NHS Trust, Royal London Hospital,
London, UK
 The Mortimer Market Centre, Central and North
West London NHS Foundation Trust
 Chelsea and Westminster Hospital NHS Foundation
Trust, London, UK
 Royal Free London NHS Foundation Trust, UK
 Kings College Hospital NHS Foundation Trust,
London, UK
 Guy’s and St Thomas’ NHS Foundation Trust,
London, UK
Participants
Clinical staff in the HIV department will identify poten-
tial participants by any of the following methods: review
of a clinic records/database, pre-identification of patients
attending for routine care, review of notes during rou-
tine clinical follow up and posters/advertisements in the
clinics to inform patients of the study.
Clinical staff identifying patients will be members of
the direct care team or research nurses or doctors work-
ing within the same HIV multidisciplinary team. A med-
ically qualified doctor on the study delegation log will
confirm eligibility.
Anonymised information on participants who are not
randomised / registered for CONSORT (16)reporting
will include the reason, if they are not eligible for trial
participation, or if they are eligible but declined.
Potentially eligible participants will be invited to attend
for an appointment, having been provided with a partici-
pant information sheet (PIS). Adequate time will be
allowed for questions and to consider the study before
agreeing to participate. The investigator or designee will
provide adequate explanation of the aims, methods, ob-
jectives and potential hazards of the study. It will also be
explained to the individual that they are free to refuse or
withdraw from the study for any reason without
Fig. 1 Trial design
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detriment to their future care or treatment. The investi-
gator can decide to withdraw a subject from the study
for urgent medical reasons or repeated non- compliance
with the study protocol. Once randomised, withdrawn
subjects may be replaced if considered necessary by the
chief investigator.
Inclusion criteria
 18 years and above
 On a bPI-based ART regimen with documented
HIV-1 RNA < 50 copies/mL for at least 6 months on
current regimen and at screening (A switch from
tenofovir disoproxil fumarate (TDF) to tenofovir ala-
fenamide (TAF), lamivudine (3TC) to emtricitabine
(FTC), or splitting co-formulated tablets to their in-
dividual component or vice versa will not be consid-
ered true regimen changes)
 Must have a historical genotype
 Eligible drug resistance mutations in historical
genotype include at least one of the following:
o M184V/I with or without any NRTI-associated
mutation (e.g. L74I/V, Y115F, K70E/G/Q/T/N/S)
o M184V/I alone (maximum of 20 participants
with isolated M184V/I mutation with or without
NNRTI mutations)
o Up to 2 TAMs (M41L, D67N, K70R, L210W,
T215F/Y, or K219Q/E/N/R) with or without
M184V/I
o Any of the above with or without NNRTI
mutations
 No previous use of any approved or experimental
INSTI
 No known INSTI mutations
 Estimated GFR ≥ 50mL/min (Cockcroft-Gault
formula)
 Have the following laboratory values at screening
within 30 days prior to baseline:
a) Alkaline phosphatase ≤3.0 x upper limit of normal
(ULN)
b) AST and ALT ≤5.0 x ULN
c) Haemoglobin ≥9.0 g/dL (female) or ≥ 10.0 g/dL
(male).
A single repeat of a laboratory screening test will be
allowed for test results that are unexpected based on
documented prior laboratory results.
 Provides written, informed consent to participate
 Is willing to comply with the protocol requirements
 If a woman and of childbearing potential and are
willing to continue practicing one of the following:
o Must be using effective birth control methods,
that is has an expected failure rate of < 1% per
year and willing to continue practicing these
birth control measures during the trial and for
at least 30 days after the end of the trial.
Effective methods include IUD, combined pill,
contraceptive injection, implant, IUS,
contraceptive vaginal ring, contraceptive patches
etc.
o Must be truly abstinent from penile-vaginal
intercourse from 2 weeks prior to administration
of study drug, throughout the study, and for at
least 30 days after the end of the trial (When this
is in line with the preferred and usual lifestyle of
the subject.) [Periodic abstinence (e.g., calendar,
ovulation, symptothermal, post-ovulation
methods), and withdrawal are not acceptable
methods of contraception].
Women who are postmenopausal for least 2 years,
women with a total hysterectomy, and women
who have a tubal ligation are considered of non-
childbearing potential.
If male, and sexually-active with female partners of
child bearing potential, is using effective barrier
contraception, and willing to continue using this
during the trial and for at least 30 days after the
end of the trial.
Exclusion criteria
 Exclusion based on drug resistance mutations
include
o Presence of any of the following mutations:
K65R/N/E
o Presence of multidrug resistance mutations:
T69ins, Q151M with or without A62V, V75I,
F77L, F116Y
o Three or more TAMs (M41L, D67N, K70R,
L210W, T215F/Y, or K219Q/E/N/R)
 Individuals experiencing decompensated cirrhosis
(e.g., ascites, encephalopathy, or variceal bleeding)
 An opportunistic illness within the 30 days prior to
screening
 Active tuberculosis infection
 Have been treated with immunosuppressant
therapies or chemotherapeutic agents within 3
months of study screening, or expected to receive
these agents or systemic steroids during the study
(e.g., corticosteroids, immunoglobulins, and other
immune- or cytokine-based therapies)
 Current alcohol or substance use judged by the
Investigator to potentially interfere with patients’
adherence to study procedure.
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 A history of malignancy of less than 5 years or
ongoing malignancy (including untreated carcinoma
in-situ) other than cutaneous Kaposi’s sarcoma (KS),
basal cell carcinoma, or resected, non-invasive cuta-
neous squamous carcinoma. Individuals with biopsy-
confirmed cutaneous KS are eligible but must not
have received any systemic therapy for KS within 30
days of Day 1 and are not anticipated to require sys-
temic therapy during the study.
 Active, serious infections (other than HIV 1
infection) requiring parenteral antibiotic or
antifungal therapy within 30 days prior to Day 1
(except if the parenteral therapy is for syphilis
infection)
 Any other clinical condition or prior therapy that
will, in the opinion of the investigator, make the
patient ineligible
 Any known allergies to the excipients of B/F/TAF
FDC
 Females who are pregnant (as confirmed by positive
urine pregnancy test)
 Women who are breastfeeding
 Women of childbearing age not using any reliable
form of contraception (e.g. intrauterine device/
intrauterine system, long-acting contraceptive
injection)
 Acute hepatitis in the 30 days prior to study entry,
anyone with hepatitis C (HCV) who is likely to need
direct acting antivirals in study
 Any concomitant medications that cannot be
administered with TAF (i.e strong inducers of p-
glycoprotein) or bictegravir (dofetilide, rifampins)
Interventions
The investigational medicinal product in this trial is Bik-
tarvy® comprising FDC of B/F/TAF. Each film-coated
tablet contains bictegravir sodium equivalent to 50 mg of
bictegravir, 200mg of emtricitabine, and tenofovir alafe-
namide fumarate equivalent to 25 mg of tenofovir
alafenamide.
Eligible individuals will either continue on their bPI
regimen (arm 1) or switch to B/F/TAF FDC (arm 2).
After 24 weeks, all participants in the bPI arm will be
switched to B/F/TAF arm and will be followed up for a
further 24 weeks whilst those immediately switched to
B/F/TAF at baseline will be followed up for 48 weeks as
illustrated in Fig. 1.
A participant is free to withdraw from the study at any
time. In addition, the investigator may decide, for rea-
sons of medical prudence, to withdraw a participant. If a
participant discontinues study medication dosing, every
attempt would be made to keep the participant in the
study and continue to perform the required study-
related procedures and follow-up procedures. If this is
not possible or acceptable to the subject or investigator,
the participant may be withdrawn from the study.
Study medication may also be discontinued in the fol-
lowing instances:
 If the participant withdraws his/her consent.
 If the investigator considers in the interest of the
subject (i.e. intercurrent illness, unacceptable
toxicity) that it is best for them to withdraw their
consent.
 The participant fails to comply with the protocol
requirements or fails to cooperate with the
investigator.
 Pregnancy during the course of the study.
The date and reasons for the withdrawal will be clearly
stated on the participant’s eCRF and source document.
Every attempt should be made to arrange follow up visits
for participants who are withdrawn from the trial (in-
cluding where individuals fall pregnant).
Participant adherence B/F/TAF and bPI will be
assessed through:
 Pill counting at each visit by a research team
member and recording of the number of pills
returned
 Self-report using a visual analogue scale (VAS)
Participants will bring in all pill bottles at each study
visit. The total number of pills remaining at each visit
will be counted and, then returned to the participant to
take until the bottle is finished. The percentage of com-
pliance for each participant will be calculated.
Participants will also be asked be asked to self-report
their level of adherence at each visit using the VAS in
which they would be asked to indicate their level of ad-
herence in the previous 30 days on a scale ranging from
0 to 100% in which 0 represents no pill taken and 100
represents every single dose had been taken. Where ad-
herence is < 80%, this will lead to likely withdrawal from
the study although this will be at the discretion of the
investigator.
Outcome measures
The primary endpoint is the proportion of participants
with HIV-1 RNA < 50 copies/mL at Week 24 using pure
virologic response (PVR).
Pure virologic response is defined as follows:
 On study treatment
 No confirmed virologic rebound defined as:
o HIV RNA ≥ 50 copies/mL on 2 consecutive visits
o HIV-1 RNA ≥ 50 copies/mL during study
followed by premature discontinuation
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 Discontinuation prior to week 24 for reasons other
than virologic rebound (i.e. no data in window and
last HIV RNA < 50 copies/mL) are considered PVR
Secondary outcome measures include the following:
 Proportion of patients with HIV RNA < 50 copies/
mL at week 48 using PVR
 Proportion of patients with HIV-1 RNA < 50 copies/
mL at weeks 24 and 48 using PVR in those with any
archived resistance detected in proviral DNA
 Emergence of new resistance mutations in
participants with two consecutive viral load ≥50
copies/mL measured 2–3 weeks apart
 Safety and tolerability of B/F/TAF FDC in
participants switching from bPI-based regimens at
48 weeks based on clinical presentation and labora-
tory results
 Change from baseline in patient reported outcomes
at weeks 24 and 48 measured using the HIV
Symptom Distress Module (HIV-SI) and the
Pittsburgh Sleep Quality Index (PSQI)
questionnaires.
 Change from baseline in serum lipid concentrations
at weeks 24 and 48
 Change from baseline in HBA1c in blood weeks 24
and 48
 Change from baseline in weight and BMI at weeks
24 and 48
Sample size justification
We considered a number of sample size scenarios bear-
ing in mind the pilot nature of the study (Table 1). We
will perform a futility analysis at 24 weeks when asses-
sing the primary outcome. At 24 weeks, with 98 partici-
pants in the trial, we will have 80% power for 10%
significance to conclude non-inferiority of the B/F/TAF
arm assuming a non-inferiority margin of 13% and viral
suppression in 90% of participants in both arms.
For the study to continue beyond 24 weeks, we need
90% (45/50) of the individuals randomised to the B/F/
TAF arm to be suppressed with the lower limit of the
confidence interval to just lie above 80%. Recruiting 50
participants per arm would achieve this at the 90% con-
fidence level. The sample size required decreases as the
level of confidence in our estimates decreases.
Recruitment
We have allowed 12months to recruit 100 participants
over the seven sites involved in the trial. This requires
recruitment of 1–2 participants per month per site
which is deemed feasible. Each site has been allocated a
target of 14–15 subjects. In the case of slow enrolment,
additional sites will be offered participation in the study.
Allocation and blinding
The web-based Sealed Envelope™ system will be used to
allocate individuals randomly to Arm 1 and Arm 2. The
statistician will provide the randomisation list. Each
study site will be provided with a randomisation guide.
The Sealed Envelope™ system will randomise subjects
within 8 strata as shown in Table 2.
The purpose of the stratification is to balance the
treatment arms on important prognostic factors such as:
 The bPI used in the subject’s baseline regimen
(Atazanavir or Darunavir)
 Use of lipid lowering therapy at study day 1 (yes/no)
 Number baseline mutations of the NRTI class (< 2
vs. ≥2)
Investigators randomise patients by completing an on-
screen form with patient details, stratification factors, in-
clusion and exclusion criteria. Investigators are immedi-
ately shown the treatment allocation. Trial managers
have real-time access to recruitment statistics and are
notified by email of every new randomisation. The ran-
domisation application conforms to the requirements of
FDA 21 CFR part 11, Electronic Records; Electronic Sig-
natures and ICH GCP. No-one can delete records from
the randomisation database, so that all randomisations
have to be accounted for. Audit log files detailing all ac-
tivity on the randomisation system are available to the
trial manager. Neither the investigators nor the partici-
pants will be blinded to the treatment allocation.
Data collection
The presence of resistance mutations will be determined
using historical genotype results obtained in local la-
boratories in those eligible according to the inclusion
and exclusion criteria. We would obtain more informa-
tion on resistance mutations by sequencing cell-
associated HIV-1 DNA in peripheral blood mononuclear
cells prior to commencing B/F/TAF. The results of
Table 1 Sample size scenarios
Confidence level Lower limit of CI Upper limit of CI Sample size per arm Total sample size
95% 80 96% 62 124
90% 80 96% 50 100
80% 80 95% 38 76
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proviral DNA sequence will not be available in real time
and will not be used to inform treatment decisions but
will further the understanding of the clinical importance
of archived resistance mutations, if any, in individuals
developing virological failure.
The baseline visit will not exceed 30 days after the
screening visit. Follow up of participants will continue
until all participants have accrued 48 weeks from their
baseline visits. Individuals who have completed Week 48
visit will be followed up 30 days post cessation of trial
treatment via a telephone call or a standard of care clin-
ical appointment for performance of the following as-
sessments; adverse events and symptoms review, HIV
associated conditions, concomitant medications and for
women of child bearing potential (WOCBP), confirm-
ation that contraception has been used in the previous
30 days.
Study procedures, screening, randomisation and safety
monitoring will be according to attached visit schedule
in Table 3.
Individuals with virological failure defined as a re-
bound in HIV-1 RNA ≥ 50 copies/mL, which is subse-
quently confirmed at the following scheduled or
unscheduled visit. Following the initial detection of viro-
logical rebound, subjects will be asked to return to the
clinic for a scheduled or unscheduled blood draw (2 to
3 weeks after the date of the first measured rebound) for
repeat viral load testing. If virological rebound is con-
firmed and the HIV-1 RNA is ≥200 copies/mL, the
blood sample from the confirmation visit will be the pri-
mary sample used for HIV-1 genotypic testing. After a
participant’s first post-baseline resistance test, additional
testing will be conducted on a case-by-case basis. Any
participant may be discontinued at the investigator’s dis-
cretion or per local treatment guidelines. If no resistance
is detected from the genotype, the participant may re-
main on study drugs and a repeat HIV-1 RNA measure-
ment should be performed (2 to 3 weeks after date of
test with HIV-1 RNA ≥ 50 copies/mL). Investigators
should carefully evaluate the benefits and risks of
remaining on study drug for each individual participant
and document this assessment in the on-site medical
record.
Data on patient reported outcome measures will be
collected using the HIV-SI and the PSQI. The HIV-SI is
a validated, self-administered 20-item health-state ques-
tionnaire for use in clinical care and research amongst
people living with HIV (PLHIV)in order to identify and
address common and bothersome symptoms associated
with HIV treatment and disease [16]. The instrument is
considered to be the gold standard in contemporary
HIV-symptom research [17]. Respondents will be asked
about their experience with each 20 symptoms during
the past 4 weeks using a 5-point Likert scale. Response
options and scores are as follows: 0) I don’t have this
symptom, 1) I have this symptom and it doesn’t bother
me, 2) I have this symptom and it bothers me a little, 3)
I have this symptom and it bothers me, 4) I have this
symptom and it bothers me a lot.
The Pittsburgh Sleep Quality Index (PSQI) is a self-
rated questionnaire which assesses sleep quality and dis-
turbances over a 30-day recall period [18]. Nineteen in-
dividual items generate seven component scores:
subjective sleep quality, sleep latency, sleep duration, ha-
bitual sleep efficiency, sleep disturbances, use of sleeping
medication, and daytime dysfunction. It uses a Likert
scale in with the following scores: 0) Not during the past
month, 1) less than once a week, 2) once or twice a
week, 3) Three or more times a week. The sum of scores
for these seven components yields one global score (0 to
21). A total score of 5 or greater is indicative of poor
sleep quality.
Participants with early study termination from what-
ever cause will undergo the assessments outlined in
Table 3.
Data management
A source data worksheet will be created to capture all
the relevant information and will be filed as source
documentation in the participants’ notes. Questionnaires
and self-report VAS scores will also be completed by the
patients. A source data agreement will be completed
Table 2 Randomisation strata
Stratum Baseline Protease-inhibitor Regimen Use of lipid lowering therapy at study day 1 No of baseline mutations of the NRTI classa
I Atazanavir Yes < 2
II Atazanavir Yes ≥2
III Atazanavir No < 2
IV Atazanavir No ≥2
V Darunavir Yes < 2
VI Darunavir Yes ≥2
VII Darunavir No < 2
VIII Darunavir No ≥2
aFrom historical genotype report assessed during screening
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Table 3 Trial procedures and Timelines
Weeks Screening
(− 30 days)
Baseline (FV) 4 12 24 (FV) 28 36 48 (FV) Early termination
visit (FV)
30 day post treatment
follow up
(telephone call or standard






Eligibility criteria X X
Review of historical drug
resistance tests
X
Adverse events X X X X X X X X X
Concomitant medications X X X X X X X X X X
HIV-SI X X X X
PSQI X X X X
HIV associated conditions X X X X X X X X X X
Randomisation X
e-Case Report Forms X X X X X X X X X X
Vital signs (Blood Pressure,
Pulse, temperature, weight)




X Xa Xa Xa Xa Xa Xa Xa Xa
Height X
Weight, BMI & waist
circumference
X X X X X X X
12 Lead ECG X X X X
Urinalysis X X X X X X X
Urine Pregnancy Test X X X X X X X
CD4/CD8 T cell count X X X X
HIV-1 RNA viral load
(& resistance testing
if > 50 copies/mL)
X X X X X X X X X
Whole blood for Proviral DNA X




X X X X X X X
Estimated GFR X X X X X X X
UPCR X X X X X X X
HBV & HCV serology X
Liver function tests X X X X X X X
Lipids (Fasting Cholesterol,
LDL, HDL, Triglycerides)
X X X X
HbA1c X X X X
Pill count adherence X X X X X X X X
Self-reported adherence X X X X X X X X
Study drug dispensation X X X X X X
Study drug accountability X X X X X X X
FV Fasting visit, HIV-SI HIV symptom distress module, PSQI Pittsburgh Sleep Quality Index, BMI Body mass index, UPCR urine protein creatinine ratio, HBV Hepatitis
B virus, HCV Hepatitis C virus, LDL Low density lipoprotein, HDL High density lipoprotein
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prior to recruitment commencing to ensure all parties
are aware which documents constitute source data.
Data from the source will be entered onto the elec-
tronic case report form (eCRF) on the web-based
MACRO™ electronic data capture system. Data entered
will be checked by the Data Manager in accordance with
the Data Management Plan (supplementary appendix)
and queries raised to the clinical sites via MACRO when
appropriate. Clinical sites will be responsible for the
entry of data into the eCRF. Patient data will be entered
using study number only and no patient identifiable data
will be seen by the data management team.
Direct access will be granted to authorised representa-
tives from the sponsor, host institution and the regula-
tory authorities when appropriate to permit trial-related
monitoring, audits and inspections.
Archiving will be the responsibility of the sponsor and
all documentation will be archived for 25 years, with the
exception of the health records which will be kept in ac-
cordance with UK law and local policy. The sponsor
named archivist will be responsible for ensuring the
documentation is prepared in line with the relevant
sponsor standard operating procedures.
Statistical analysis
All randomised patients who received at least one dose
of the study medication will be included in the analysis.
Summary statistics will be presented by trial arm using
median with interquartile ranges for continuous variables
with skewed distributions or mean with standard deviations
for normally distributed variables. Categorical variables will
be summarised using frequencies and proportions.
Non-inferiority for the futility analyses will be con-
cluded if the lower bound of a two-sided 90% CI for the
difference in proportions (B/F/TAF minus boosted PI) of
patients with plasma HIV-1 RNA < 50 copies/mL at
week 24 is greater than − 13%.
Primary outcome analyses
Primary efficacy endpoint Proportions of individuals
with HIV RNA < 50 copies/mL at 24 weeks will be esti-
mated using PVR.
The percentage of participants with PVR for HIV-1
RNA cut-off at 50 copies/mL at Week 24 will be
summarized.
Differences between trial arms will be estimated to-
gether with 95% confidence intervals.
Secondary outcome analysis
Secondary efficacy endpoint Proportions of individuals
with HIV RNA < 50 copies/mL at 48 weeks will be esti-
mated using PVR.
The percentage of participants with PVR for HIV-1
RNA cut-off at 50 copies/mL at Week 48 will be
summarized.
Differences between trial arms will be estimated, to-
gether with 95% confidence intervals. The proportion of
patients with HIV-1 RNA < 50 copies/mL at weeks 24
and 48 using PVR in those with any archived resistance
detected in proviral DNA will be estimated.
The proportion of patients with any emergent drug re-
sistance following virological rebound will be estimated.
Safety endpoints
The analysis of the following secondary safety outcomes
will be presented as the estimated difference and 95%
confidence interval between arms from baseline to 24
and 48 weeks
 Mean total Cholesterol, LDL, HDL and triglycerides
will be estimated.
 Mean HBA1c
 Mean weight and BMI
 Laboratory and clinical adverse events will be
described and summarised using percentages.
Treatment differences for patient reported outcomes
using the HIV-SI module and the PSQI will be com-
pared by using the prevalence of symptoms reported by
each method and presented with 95% confidence inter-
vals. Consistent with prior analyses on HIV-SI [19, 20]
we would dichotomise symptoms into not bothersome
(scores of 0 or 1) or bothersome (scores of 2, 3 and 4).
The overall bothersome symptom count at baseline will
be generated by counting the number of individual
symptoms scored as bothersome. Reported poor sleep
quality scores on the PSQI will be summarised by the
seven components as well as the global scores by arm.
The global scores will be dichotomised into poor sleep
quality (score of < 5) and good sleep quality (≥5) and an
exact 95% binomial confidence interval presented for the
difference in prevalence between arms. .
In the event of missing data, only available data will be
included in the analyses and missing data will be quanti-
fied but not imputed. For missing data relating to pri-
mary and secondary efficacy endpoints, using the
principle of PVR, the last known measured viral loads
will be carried forward if data is missing at the 24 and
48 week time points.
Data safety monitoring board
A three-member independent data safety monitoring
board (DSMB) has been established comprising special-
ists in clinical infectious diseases, HIV medicine and a
clinical trial statistician. The role of the DSMB will be to
safeguard the interest of the trial participants, assess
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safety and efficacy of the intervention and to monitor
the overall conduct of the trial. The DSMB should re-
ceive and review the progress and accruing data of the
trial and provide advice on the conduct of the trial to
the Trial Steering Committee (TSC). The DSMB would
perform an interim review of the trial’s progress includ-
ing updated figures on recruitment, data quality, main
outcomes and safety data and will have responsibility on
the decision whether to stop or continue the trial. The
DSMB will meet six-monthly but the frequency of meet-
ings may depend on recruitment rates or other trial
events. Further details on the DSMB charter can be
found in the supplementary appendix.
Adverse events monitoring and reporting
Information on all adverse events (AEs), adverse reac-
tions (ARs), serious adverse reactions (SARs), suspected
unexpected serious adverse reactions (SUSARs) and ser-
ious adverse events (SAEs) will be documented in the
case report forms. AEs, SAEs, ARs, SARs and SUSARs
may be directly observed, reported spontaneously by the
participant or by questioning the participant at each
study visit. These will be followed up until they are re-
solved or the participant’s participation in the study ends
(i.e. until the final CRF is completed for that participant).
Any untoward event that may occur subsequent to the
reporting period that the investigator assesses as related
to the study drug medication will also be reported as an
adverse event. The adverse event reporting period will
be from consent until the participant’s final study visit.
After informed consent, but prior to initiation of study
treatment, all SAEs and adverse events related to
protocol-mandated procedures would be reported on
the CRFs. Following initiation of study treatment, all
AEs, regardless of cause or relationship until 30 days
post cessation of trial treatment would be reported on
the CRFs. In addition, all serious adverse events assessed
by the investigator as related to the investigational medi-
cation would continue to be followed even after partici-
pation in the study is over. Such events would be
followed until resolution, or until no further change can
reasonably be expected.
Research ethics and consent
This study is registered with the International Standard
Randomised Controlled Trials Number registry
(44453201) and with the European Union Drug Regulat-
ing Authorities Clinical Trials Database (2018–004732-
30). The main study findings will be reported in accord-
ance the Consolidated Standards of Reporting Trials
(CONSORT) statement [21]. The study received ethical
approval from the Health Research Authority (19/LO/
0905) and will be conducted in accordance with the
Declaration of Helsinki. Written, informed consent will
be sought from participants by an appropriate member
of the research team identified on the delegation log and
this is mandatory prior to any study procedures. Partici-
pants would be made aware that they may not continue
to be prescribed B/F/TAF after the end of the trial un-
less they are eligible according to NHS England prescrib-
ing criteria for tenofovir alafenamide. In this situation,
participants would be switched to alternative efficacious
ART combination decided by the local principal
investigator.
Data protection and patient confidentiality
All investigators and trial site staff will comply with the
requirements of the General Data Protection Regulation
2018 (GDPR) [22] with regards to the collection, storage,
processing and disclosure of personal information and
will uphold the Act’s core principles. Personal informa-
tion will be collected, kept secure, and maintained. This
will involve the creation of coded, depersonalised data
where the participant’s identifying information is re-
placed by an unrelated sequence of characters, secure
maintenance of the data and the linking code in separate
locations using encrypted digital files within password
protected folders and storage media and limiting access
to the minimum number of individuals necessary for
quality control, audit, and analysis. The confidentiality of
data will also be preserved when the data are transmitted
to sponsors and co-investigators by using only pseudo-
nymised codes rather than personal identifiable informa-
tion. Trial data will be stored for 25 years and the
principal investigator at site is the data custodian.
Discussion
It is plausible that carefully selected HIV-positive indi-
viduals with pre-treatment or treatment-acquired resist-
ance who are virologically suppressed on their current
PI-based regimen could maintain virological efficacy
when switched to B/F/TAF FDC.
The hypothesis is based on a consideration of each
component of B/F/TAF. TAF, like the earlier version
tenofovir disoproxil fumarate (TDF), is a prodrug of
tenofovir. However, TAF yields 5-fold higher intracel-
lular concentrations of the active moiety tenofovir di-
phosphate (TFV-DP) in HIV target cells than TDF,
despite much lower plasma drug concentration [23]..
Since TAF and TDF produce the same active metab-
olite, they have similar resistance profiles but it could
be proposed that the higher intracellular concentra-
tions of TFV-DP yielded by TAF could be beneficial
in resistant viral isolates [24]. Furthermore, the select-
ive conversion of TAF to TFV-DP within HIV target
cells and lower levels in plasma is associated with less
renal and bone toxicity [25].
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HIV-1 strains harbouring the M184V/I mutation,
which causes high-level resistance to 3TC and FTC, dis-
play increased or restored susceptibility to tenofovir
[26]. M184V/I mutants also display a loss of fitness that
reduces their replication capacity and may account for
the partial residual activity of 3TC in the presence of the
mutation. In ART-experienced individuals who devel-
oped virological failure whilst treated with either zidovu-
dine or stavudine, the stepwise accumulation of TAMs
resulted in increasing resistance to tenofovir, with three
or more TAMs being associated with markedly reduced
tenofovir susceptibility [27]. This cross resistance to
tenofovir is more marked for the TAM-1 pathway of
mutations (M41L, L210W, and T215Y) than the TAM-2
pathway of mutations (D67N, K70R, K219/E/N/Q/R,
and T215F). As a result, we have allowed a maximum of
2 TAMs when assessing eligibility for inclusion in the
trial. The revertant mutations T215S/C/D/E/I/V/N/A/L
which arise from viruses that once harboured T215Y/F
do not directly impact NRTI susceptibility [28]. How-
ever, both in vitro and in vivo, the effect of TAMs on
tenofovir is partially reversed by the presence of the
M184V/I mutation [29, 30] with 3TC maintaining re-
sidual activity in viruses harbouring this mutation [31].
Bictegravir has potent in vitro activity against labora-
tory strains and clinical isolates of HIV-1, a higher gen-
etic barrier to resistance development than raltegravir
(RAL) and elvitegravir (EVG), and a statistically im-
proved resistance profile compared to RAL, EVG, and
DTG against a set of patient derived INSTI-resistant
viral isolates [32]. In the EARNEST [33], and MOBIDIP
[31] studies, bPI given with NRTI in individuals with
previous virological failure and predicted limited NRTI
activity due to resistance (mainly M184V/I and TAMs)
achieved high rates of virological suppression. In the
DAWNING study [12], DTG a high genetic barrier
INSTI, demonstrated superior virological efficacy over a
bPI. Hence there is a strong scientific plausibility for bic-
tegravir demonstrating high rates of virological efficacy
in the presence of a limited pattern NRTI mutations
when switching patients from bPI regimen to B/F/TAF.
We do not foresee a challenge to recruiting the 100
participants required for this trial, however recruitment
will be monitored closely and if sluggish, we would acti-
vate additional sites for participation in the study. Since
all sites will be utilising standardised study documents
and procedures, the number of study sites should not
affect data quality. Furthermore, all sites will be closely
monitored for compliance with the study protocol.
Trial status
The trial started enrolling participants on 16 September
2019 and it is anticipated that enrolment will continue
until September 2020.
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